肿瘤细胞治疗研究
英文原题：How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
细胞疗法数十年来一直是套细胞淋巴瘤（MCL）治疗的基石，并显著改善了这种既往预后极差的B细胞淋巴瘤的结局。
细胞疗法数十年来一直是套细胞淋巴瘤（MCL）治疗的基石，并显著改善了这种既往预后极差的B细胞淋巴瘤的结局。目前细胞疗法的既定作用包括：作为一线治疗组成部分的自体造血细胞移植（HCT）、用于复发/难治性MCL的嵌合抗原受体工程T细胞（CART），以及在CART治疗失败或不可及情况下的异基因HCT。治疗创新近期已进入MCL治疗领域，并在治疗流程中向前推进，对现有管理原则提出了挑战。本文旨在就如何在日益复杂的环境中最佳使用细胞疗法提供一些指导。由于CART标签、可用的非细胞治疗选择以及美国和欧洲卫生体系理念之间的差异，我们认为针对既定标准场景对比美国和欧洲的视角是合理的，这些场景往往相互重叠，但在一些重要方面存在差异。
Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.
MEMBER ACCOUNT
登录成功会直接打开下一页。
